4967 KOBAYASHI PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4967

TSE Prime

KOBAYASHI PHARMACEUTICAL CO.,LTD.

5,994

JPY

+32

(+0.54%)

Dec 23, 3:30 pm JST

38.27

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

6,009

Dec 23, 3:24 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020	150,514	25,943	27,726	19,205	245.7	77	Feb 1, 2021	J-GAAP
Dec, 2021	155,252	26,065	28,015	19,715	252.4	83	Feb 4, 2022	J-GAAP
Dec, 2022	166,258	26,669	28,281	20,022	259.6	90	Feb 14, 2023	J-GAAP
Dec, 2023	173,455	25,780	27,330	20,338	268.2	101	Feb 9, 2024	J-GAAP
Dec, 2024 Guidance	169,000	24,000	25,500	10,700	143.9	102	Nov 8, 2024	J-GAAP
YoY	-2.6%	-6.9%	-6.7%	-47.4%	-46.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2019	Jan 31, 2019	173,000	27,300	27,900	19,000	68	J-GAAP
Results	Jan 31, 2020	158,340	25,658	27,851	19,139	73	J-GAAP
Dec, 2020	Jan 31, 2020	Available in future release
	Jul 30, 2020
Results	Feb 1, 2021
Dec, 2021	Feb 1, 2021
	Jul 29, 2021
Results	Feb 4, 2022
Dec, 2022	Feb 4, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
	Aug 8, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024	185,600	26,300	27,500	20,500	103	J-GAAP
- - - -	May 10, 2024	ー	ー	ー	ー	103	J-GAAP
- - - -	Aug 8, 2024	169,000	24,000	25,500	12,100	102	J-GAAP
	Nov 8, 2024	169,000	24,000	25,500	10,700	102	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	180,731	+8.5	Available in future release
Mar, 2001	185,001	+2.4
Mar, 2002	204,647	+10.6
Mar, 2003	210,922	+3.1
Mar, 2004	211,670	+0.4
Mar, 2005	215,708	+1.9
Mar, 2006	246,852	+14.4
Mar, 2007	257,022	+4.1
Mar, 2008	228,826	-11.0
Mar, 2009	125,693	-45.1
Mar, 2010	129,184	+2.8
Mar, 2011	130,824	+1.3
Mar, 2012	131,166	+0.3
Mar, 2013	121,532	-7.3
Mar, 2014	127,293	+4.7
Mar, 2015	128,344	+0.8
Mar, 2016	137,211	+6.9
Dec, 2016 Changed	120,051	－
Dec, 2017	156,761	+30.6
Dec, 2018	167,479	+6.8
Dec, 2019	158,340	-5.5
Dec, 2020	150,514	-4.9
Dec, 2021	155,252	+3.1
Dec, 2022	166,258	+7.1
Dec, 2023	173,455	+4.3
Dec, 2024 Guidance	169,000	-2.6	24,000	-6.9	25,500	-6.7	143.9	-46.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2022	166,258	26,669	16.0	10.18	7.88	0.65	259.6
Dec, 2023	173,455	25,780	14.9	10.12	7.77	0.66	268.2
Dec, 2024 Guidance	169,000	24,000	14.2	5.24	4.27	0.67	143.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	257,022	26,669	28,281	20,338	268.2
Fiscal Year	Mar, 2007	Dec, 2022	Dec, 2022	Dec, 2023	Dec, 2023

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	88,200	15,825	16,924	11,834	151.5	46	Feb 4, 2022	J-GAAP
Jul - Dec, 2022	94,994	16,801	17,377	12,322	159.8	52	Feb 14, 2023	J-GAAP
Jul - Dec, 2023	99,830	15,374	16,156	12,474	164.5	58	Feb 9, 2024	J-GAAP
Jul - Dec, 2024 Guidance	95,864	14,529	15,066	9,264	124.6	59	Nov 8, 2024	J-GAAP
YoY	-4.0%	-5.5%	-6.7%	-25.7%	-24.2%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	26,065	30,410	22,419	7,991	-10,377	81,987	32.46	J-GAAP
Dec, 2022	26,669	17,602	31,914	-14,312	-20,759	79,480	31.07	J-GAAP
Dec, 2023	25,780	-1,216	18,360	-19,576	-19,463	59,690	22.32	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	114,279	18,749	20,433	14,500	187.5	72.2	Nov 1, 2022	J-GAAP
Jan - Sep, 2023	119,115	19,387	20,837	15,498	203.6	76.2	Nov 7, 2023	J-GAAP
Jan - Sep, 2024	114,459	16,976	17,921	5,344	71.9	70.3	Nov 8, 2024	J-GAAP
YoY	-3.9%	-12.4%	-14.0%	-65.5%	-64.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	51,979	7,920	7,848	5,522	71.6	15.2	Feb 14, 2023	J-GAAP
Jan - Mar, 2023	33,467	5,061	5,168	3,608	47.4	15.1	May 10, 2023	J-GAAP
Apr - Jun, 2023	40,158	5,345	6,006	4,256	55.9	13.3	Aug 8, 2023	J-GAAP
Jul - Sep, 2023	45,490	8,981	9,663	7,634	100.3	19.7	Nov 7, 2023	J-GAAP
Oct - Dec, 2023	54,340	6,393	6,493	4,840	63.8	11.8	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	36,485	5,028	5,461	976	13.1	13.8	May 10, 2024	J-GAAP
Apr - Jun, 2024	36,651	4,443	4,973	460	6.2	12.1	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	41,323	7,505	7,487	3,908	52.6	18.2	Nov 8, 2024	J-GAAP
YoY	-9.2%	-16.4%	-22.5%	-48.8%	-47.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	47,138	-8.8	Available in future release
Jan - Mar, 2020	31,911	+0.7
Apr - Jun, 2020	34,269	-9.0
Jul - Sep, 2020	38,869	-7.2
Oct - Dec, 2020	45,465	-3.5
Jan - Mar, 2021	30,269	-5.1
Apr - Jun, 2021	36,783	+7.3
Jul - Sep, 2021	40,606	+4.5
Oct - Dec, 2021	47,594	+4.7
Jan - Mar, 2022	32,646	+7.9
Apr - Jun, 2022	38,618	+5.0
Jul - Sep, 2022	43,015	+5.9
Oct - Dec, 2022	51,979	+9.2
Jan - Mar, 2023	33,467	+2.5
Apr - Jun, 2023	40,158	+4.0
Jul - Sep, 2023	45,490	+5.8
Oct - Dec, 2023	54,340	+4.5
Jan - Mar, 2024	36,485	+9.0
Apr - Jun, 2024	36,651	-8.7
Jul - Sep, 2024	41,323	-9.2	7,505	-16.4	7,487	-22.5	52.6	-47.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	71,727	9,295	10,013	7,634	100.3
Fiscal Year	Dec, 2007	Sep, 2020	Sep, 2020	Sep, 2023	Sep, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Announce	Accounting Standards
Dec, 2021	2,515.53	77.4	252,554	195,547	200,534	Feb 4, 2022	J-GAAP
Dec, 2022	2,600.04	77.3	255,827	197,639	194,285	Feb 14, 2023	J-GAAP
Dec, 2023	2,749.17	76.4	267,473	204,370	205,681	Feb 9, 2024	J-GAAP
Jan - Sep, 2024	ー	81.5	250,484	204,033	203,518	Nov 8, 2024	J-GAAP

KOBAYASHI PHARMACEUTICAL CO.,LTD.(4967) Financial Results